{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Zhang K"],"pubmed_abstract":["<b>Introduction:</b> Extensive use of antiretroviral therapy has remarkably improved the survival rates of people living with HIV. Doravirine (DOR) is a newly-approved antiretroviral belonging to the class of non-nucleoside reverse transcriptase inhibitors. Here, we compared the efficacy and safety of DOR + tenofovir dipivoxil fumarate (TDF)+Lamivudine (3TC)/Emtritabine (FTC) with traditional triple therapies in treatment-naïve HIV-1-positive adults. <b>Methods:</b> Randomized controlled trials involving treatment-naïve HIV-1-positive adults that met inclusion criteria were systematically retrieved and data on the following outcomes extracted: virological suppression, adverse events, severe adverse events, and drug-related adverse events. A Bayesian network meta-analysis was then performed"],"journal":["Frontiers in pharmacology"],"pagination":["676831"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9065253"],"repository":["biostudies-literature"],"pubmed_title":["Comparison of the Efficacy and Safety of a Doravirine-Based, Three-Drug Regimen in Treatment-Naive HIV-1 Positive Adults: A Bayesian Network Meta-Analysis."],"pmcid":["PMC9065253"],"pubmed_authors":["Xu L","Zhang K","Zhang Y","Zhou C","Huang X","Chen G","Zhou J"],"additional_accession":[]},"is_claimable":false,"name":"Comparison of the Efficacy and Safety of a Doravirine-Based, Three-Drug Regimen in Treatment-Naive HIV-1 Positive Adults: A Bayesian Network Meta-Analysis.","description":"<b>Introduction:</b> Extensive use of antiretroviral therapy has remarkably improved the survival rates of people living with HIV. Doravirine (DOR) is a newly-approved antiretroviral belonging to the class of non-nucleoside reverse transcriptase inhibitors. Here, we compared the efficacy and safety of DOR + tenofovir dipivoxil fumarate (TDF)+Lamivudine (3TC)/Emtritabine (FTC) with traditional triple therapies in treatment-naïve HIV-1-positive adults. <b>Methods:</b> Randomized controlled trials involving treatment-naïve HIV-1-positive adults that met inclusion criteria were systematically retrieved and data on the following outcomes extracted: virological suppression, adverse events, severe adverse events, and drug-related adverse events. A Bayesian network meta-analysis was then performed","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-26T15:20:17.485Z","creation":"2025-04-06T14:51:00.741Z"},"accession":"S-EPMC9065253","cross_references":{"pubmed":["35517782"],"doi":["10.3389/fphar.2022.676831"]}}